Displaying drugs 2526 - 2550 of 3590 in total
CHS-828
CHS-828 has been used in trials studying the treatment of Unspecified Adult Solid Tumor, Protocol Specific.
Investigational
MK-8245
MK-8245 has been used in trials studying the treatment of Type 2 Diabetes Mellitus.
Investigational
MK-8666
MK-8666 is under investigation in clinical trial NCT01971554 (Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of MK-8666 in Participants With Type 2 Diabetes Mellitus (MK-8666-003)).
Investigational
Matched Iupac: … (2S,3S,4R)-8-{[4'-(3-methanesulfonylpropoxy)-2',6'-dimethyl-[1,1'-biphenyl]-3-yl]methoxy}-9-azatricyclo …
PEN-866
PEN-866 is under investigation in clinical trial NCT03221400 (PEN-866 in Patients With Advanced Solid Malignancies).
Investigational
BBP-812
Investigational
MK-8719
Investigational
AB-8939
Investigational
VTX-801
VTX-801 is a replication-deficient recombinant adeno-associated viral vector (rAAV) consisting of an AAV liver tropic capsid containing a single-stranded DNA genome carrying a shortened version of the ATP7B gene (ATP7B-minigene). It is being investigated in Wilson Disease.
Investigational
OBI-888
Investigational
BBT-877
BBT-877 is an autotaxin enzyme inhibitor being investigated for the treatment of fibrotic diseases, such as idiopathic pulmonary fibrosis.
Investigational
Octamethylenediamine
Experimental
Selicrelumab
Selicrelumab is under investigation in clinical trial NCT01008527 (Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100).
Investigational
VMD-928
Investigational
CRA_10991
Experimental
CRA_10762
Experimental
RB106
Experimental
CRA_10972
Experimental
CRA_10656
Experimental
TG-100801
TG100801 is a topically applied kinase inhibitor in macular degeneration patients. It is administered noninvasively as an eye drop and is designed to suppress VEGF mediated leakage and additional kinase targets associated with inflammation, edema, and angiogenesis which are the pathological hallmarks of AMD and other back of the eye...
Investigational
CPG 10101
CPG 10101 is a synthetic oligodeoxynucleotide (ODN) in clinical trials. It is a toll-like receptor 9 (TLR9) agonist with antiviral and immunomodulatory properties that could potentially influence chronic infection with HCV.
Investigational
KB109
KB109 is a prebiotic to feed healthy bacteria for them to to outcompete multi-drug resistance organisms.
Investigational
P-BCMA-101
P-BCMA-101 is an autologous CAR-T therapy developed using Poseida’s piggyBac platform technology.
Investigational
AP103
AP103 is a non-viral gene therapy that uses a delivery vector, HPAE (Highly Branched Poly β-Amino Ester), to deliver the correct collagen VII gene into skin cells.
Investigational
Displaying drugs 2526 - 2550 of 3590 in total